This webinar is aimed at informing end-users involved in pre-clinical drug screening (discovery and development) of the models and techniques available to elucidate the causes and consequences of gastrointestinal (GI) toxicities and pathologies. This information will ultimately help users design dose schedules and formulations that can minimise such effects, or quickly identify test articles that have a high likelihood of toxicity in vivo or in the clinic. Dr. Booth has been a key opinion leader is this field for 25 years, working with many different biotechnology and pharmaceutical companies to design and perform studies that address their pertinent questions. This webinar will review some of the models in use and discuss current practice when running pre-clinical studies for sponsors at Epistem. Specifically, there will be an overview of:
Historical data will be presented to illustrate the techniques and responses to known therapeutics, along with typical study designs and readouts.
The aim of this webinar is to enable the end-user to select the best model and study design to predict or assess GI toxicity.